Context Therapeutics Turns Focus to Compelling Clinical Development Candidate

Context Therapeutics (Nasdaq: CNTX), a biopharmaceutical company developing novel treatments for solid tumors, continues to respond to the large unmet need for targeted therapies to treat solid tumors with the development of its preclinical asset, CTIM-76.

CTIM-76 targets Claudin 6 (CLDN6), a validated therapeutic target for many solid tumor types, including ovarian, endometrial, testicular, and gastric.

The company will present preclinical data regarding CTIM-76 at the American Association for Cancer Research (AACR) Annual Meeting 2023 this month.


 In January 2023, Context entered a manufacturing agreement with global development and manufacturing company, Lonza, to manufacture CTIM-76.

Context has initiated IND-enabling studies and expects to submit an IND Application to support human clinical trials for CTIM-76 in Q1 2024.

Cash, cash equivalents, and restricted cash were $35.5 million at December 31, 2022. Context expects this runway will be sufficient to fund operations into late 2024.

Context will participate in two investor conferences in April: the Diamond Equity Emerging Growth Invitational Investor Conference on April 5 and the 22nd Annual Needham Virtual Healthcare Conference on April 19. The company will also participate in one-on-one meetings.

In March, 2023 Context announced it would discontinue the development of ONA-XR, due to the increasingly competitive landscape for breast cancer treatments, instead turning its focus to CTIM-76.

 About Context Therapeutics

Context Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical company committed to advancing medicines for solid tumors. The company’s pipeline includes small molecule and bispecific antibody drug candidates that target cancer signaling pathways.  is developing CTIM-76, a selective Claudin 6 (CLDN6) x CD3 bispecific antibody for CLDN6-positive tumors, currently in preclinical development.

Share This Article


About the Author

Context Therapeutics Turns Focus to Compelling Clinical Development Candidate

Editor Prism MarketView